BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 17, 2026
See today's BioWorld
Home
» ChemoCentryx Partners With GSK's CEEDD In $1.5B Deal
To read the full story,
subscribe
or
sign in
.
ChemoCentryx Partners With GSK's CEEDD In $1.5B Deal
Aug. 25, 2006
By
Karen Carey
In a worldwide multi-target alliance focused on treatments for inflammatory disorders, ChemoCentryx Inc. signed a deal potentially worth $1.5 billion with GlaxoSmithKline plc. (BioWorld Today)
BioWorld
